
MALI Platform
AI Stock Research
Alphabet Inc.: latest 13F holdings
For the quarter ending 30 September 2026, Alphabet Inc. reported 29 positions worth $88.3B in total, filed with the SEC on 6 November 2026. The quarter before, it reported $99.1B.
Read the filing at SEC EDGARChecked: the cover page's entry count and total value match the holdings table.
Top 29 positions by value
| # | Issuer | Class | Value | Weight | Shares | vs quarter before |
|---|---|---|---|---|---|---|
| 1 | SPACE EXPLORATION TECHN CORP | CLASS A COM STK | $83.7B | 94.78% | 555,043,560 | Added 0.7% |
| 2 | CME GROUP INC | COM | $912.7M | 1.03% | 3,484,020 | Unchanged |
| 3 | PLANET LABS PBC | COM CL A | $577.7M | 0.65% | 35,248,893 | Unchanged |
| 4 | ARM HOLDINGS PLC | SPONSORED ADS | $568.0M | 0.64% | 1,960,784 | Unchanged |
| 5 | REVOLUTION MEDICINES INC | COM | $548.8M | 0.62% | 2,673,909 | Cut 9.3% |
| 6 | QUALCOMM INC | COM | $547.9M | 0.62% | 2,976,982 | New |
| 7 | AST SPACEMOBILE INC | COM CL A | $526.4M | 0.60% | 8,943,486 | Unchanged |
| 8 | FRESHWORKS INC | CLASS A COM | $183.4M | 0.21% | 14,336,643 | Cut 11.5% |
| 9 | PARABILIS MEDICINES INC | COM | $158.9M | 0.18% | 4,919,498 | Unchanged |
| 10 | TEMPUS AI INC | CL A | $127.0M | 0.14% | 1,551,102 | Unchanged |
| 11 | UIPATH INC | CL A | $90.3M | 0.10% | 7,034,337 | Unchanged |
| 12 | NEUTRON HOLDINGS INC | COM | $53.5M | 0.06% | 1,898,948 | New |
| 13 | PRIME MEDICINE INC | COM | $50.7M | 0.06% | 16,562,498 | Unchanged |
| 14 | PAYPAY CORP | SPONSORED ADS | $49.1M | 0.06% | 3,125,000 | Unchanged |
| 15 | MAZE THERAPEUTICS INC | COM | $37.7M | 0.04% | 1,388,583 | Unchanged |
| 16 | FREENOME INC | COMMON STOCK | $31.8M | 0.04% | 2,022,131 | New |
| 17 | RELAY THERAPEUTICS INC | COM | $25.5M | 0.03% | 1,410,029 | Unchanged |
| 18 | FERVO ENERGY CO | CL A COM | $23.9M | 0.03% | 1,760,732 | Unchanged |
| 19 | ETHOS TECHNOLOGIES INC | CL A | $19.2M | 0.02% | 571,907 | Cut 84.2% |
| 20 | OBSIDIAN THERAPEUTICS INC | COM | $16.8M | 0.02% | 1,224,869 | New |
| 21 | OSCAR HEALTH INC | CL A | $14.9M | 0.02% | 481,988 | Unchanged |
| 22 | BRIDGEBIO ONCOLOGY THERAPEUT | COM NEW | $11.6M | 0.01% | 2,823,126 | Unchanged |
| 23 | SANA BIOTECHNOLOGY INC | COM | $8.2M | 0.01% | 2,812,500 | Unchanged |
| 24 | BEAM THERAPEUTICS INC | COM | $7.9M | 0.01% | 321,604 | Unchanged |
| 25 | VERA THERAPEUTICS INC | CL A | $7.8M | 0.01% | 241,264 | Unchanged |
| 26 | FIGMA INC | CLASS A COM STK | $4.5M | 0.01% | 215,582 | Unchanged |
| 27 | MONTE ROSA THERAPEUTICS INC | COM | $4.4M | 0.01% | 372,474 | Unchanged |
| 28 | LYELL IMMUNOPHARMA INC | COM NEW | $2.9M | 0.00% | 293,256 | Unchanged |
| 29 | HYPERFINE INC | COM CL A | $728.0K | 0.00% | 898,720 | Unchanged |
New this quarter
- QUALCOMM INC · $547.9M
- NEUTRON HOLDINGS INC · $53.5M
- FREENOME INC · $31.8M
- OBSIDIAN THERAPEUTICS INC · $16.8M
Sold out
- GITLAB INC · was $83.2M
- SPERO THERAPEUTICS INC · was $2.0M
- AUTOLUS THERAPEUTICS PLC · was $1.1M
Reading a 13F
A 13F lists a manager's long positions in US-listed securities at the end of a quarter, filed up to 45 days later. It leaves out short positions, cash and most non-US holdings, so it is a partial, delayed view of a portfolio. Nothing here is investment advice.
Positions are named as the manager filed them. Values are the filing's own, in US dollars; changes compare share counts with the quarter before.